Dr. Ansbert Gadicke is the Managing Partner of MPM BioImpact. Ansbert founded MPM Capital in 1992 as a biotech venture capital firm and later its affiliate BioImpact Capital for private/public funds. He is the driving force at MPM BioImpact behind building leading companies such as BioMarin Pharmaceuticals (NASDAQ: BMRN), Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), TriNetX, and Pharmasset (acquired by Gilead Sciences) and, more recently, Cullinan Therapeutics (NASDAQ: CGEM), ElevateBio and Orna Therapeutics. MPM BioImpact believes that these companies, in which Ansbert was the lead investor and served on the Boards of Directors, are some of the biggest successes in biotech – companies that ultimately result in helping thousands of patients live longer and vastly improved lives. For example, Sovaldi, developed by Pharmasset, was the first cure for Hepatitis C, the most successful product launch in the pharmaceutical industry and has today cured over 6 million patients of Hepatitis. Prior to founding MPM, Ansbert was at The Boston Consulting Group in their Boston office.

Ansbert’s commitment to drug discovery and curing disease inspires his work both within and outside of MPM BioImpact. In recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Ansbert is a recipient of the 2017 Global Oncology Visionary Award. He is a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.

Ansbert received an M.D. from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University. While at the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.

Dr. David Kolesky is a Principal at MPM BioImpact. He is responsible for driving investments and company creation activities.

Before joining MPM BioImpact, David was a Principal at Flagship Pioneering, where he focused on conceiving, creating, and operating new bioplatform technology companies. David co-founded and helped launch several companies, notably Senda Biosciences and Montai Health, where he held key leadership roles at early stages of development including Chief Scientific Officer and Chief Innovation Officer at Montai, and Head of Platform at Senda. David has developed a wide range of scientific and technical experience by working across diverse platforms, including AI-enabled small molecule discovery, programmable delivery of genomic medicines, and cell & tissue engineering.

David received his Ph.D. in Engineering Sciences from Harvard University and conducted a postdoctoral fellowship at the Wyss Institute for Biologically Inspired Engineering. Working with Professor Jennifer Lewis at Harvard, he invented various technologies for creating vascularized kidney tissues for drug screening and tissue replacement. His work has been published in top journals and he is co-inventor of several issued patents. David has received numerous awards, including the National Inventor’s Hall of Fame Collegiate Inventor Prize.

A native of South Florida, David received his B.S in Materials Science and Engineering from the University of Florida.

Dr. Grey Sieczkiewicz serves as IP Counsel to several MPM BioImpact portfolio companies.

Prior to joining MPM BioImpact, Grey was the IP strategy architect for more than a dozen venture-backed life sciences companies across the spectrum—from nucleic acid therapeutics, oral biologics and the microbiome to oncology and protein engineering. He has served as Vice President, IP at Flagship Ventures, and also practiced patent counseling and enforcement at national law firms Mintz Levin, Proskauer Rose and Foley Hoag. Grey is a member of the bar of the Commonwealth of Massachusetts and is admitted to practice before the U.S. Patent and Trademark Office. He is also the former President of the Boston Patent Law Association.

Grey received his J.D., magna cum laude, from the evening program of Suffolk University Law School and earned his Ph.D. in Cell, Molecular and Developmental Biology from Tufts University School of Medicine and completed his post-doctoral fellowship at the National Cancer Institute. He received his A.B. in Biology from the College of the Holy Cross.

Dr. Frank Neumann is an Entrepreneur Partner at MPM BioImpact and Acting Chief Medical Officer of Orna Therapeutics, an MPM BioImpact portfolio company. Frank brings extensive experience and proven leadership in cell therapy and oncology clinical development to these roles.

Prior to joining MPM BioImpact, Frank served as Senior Vice President and Global Head of Clinical Development at Kite, a Gilead Company. Previously Frank held positions as Acting Chief Medical Officer at Verastem, Inc. (also known as Verastem Oncology) and Vice President, Head of Oncology Clinical Research at bluebird bio. In addition, he was clinical development head of global cell therapy approaches at Takeda Pharmaceuticals, where he also held various leadership roles of increasing prominence including global clinical lead and medical team lead for two distinct cancer therapies. Earlier in his career, Frank was a member of the oncology medical teams at AstraZeneca and Sanofi-Aventis.

Board certified in Hematology/Oncology, Internal Medicine and Palliative Care Medicine, Frank was a research scholar at the University of Texas MD Anderson Cancer Center and is currently an assistant professor at the Heinrich Heine University in Düsseldorf, Germany, where he received his M.D. He earned his Ph.D. from the Rheinische-Friedrich-Wilhelm University in Bonn, Germany.

Dr. Jin Wang is Vice President of Clinical Development at K2 Therapeutics, where she leads global development strategies and supports investment, search and evaluation, and business development initiatives. With 15 years of drug development experience, Dr. Wang has directed programs spanning early to late phases, including globally approved Tislelizumab and Zanidatamab.

Before joining K2, Dr. Wang held senior leadership roles across global biopharma. At Gilead Sciences, she led clinical development for the APAC region. As Chief Medical Officer at Ablaze Pharmaceuticals, she advanced a radiopharmaceutical pipeline to IND-enabling stages prior to its acquisition by Bristol Myers Squibb. At BeiGene, she directed global development strategies and cross-functional teams for major oncology assets.

Her earlier career includes impactful contributions at Eli Lilly and IQVIA, as well as hands-on patient care at Shanghai Changzheng Hospital.

Dr. Wang holds an MD and PhD in Medicine and is board-certified in Medical Oncology.

Wu Jie is the Head of APAC at MPM BioImpact, where she focuses exclusively on early-stage investment and company creation opportunities in the region.

Prior to joining MPM BioImpact, Wu Jie spent 16 years with Temasek and invested in healthcare companies across different geographies and subsectors, including Juno Therapeutics, Guardant Health and JW Therapeutics. She most recently served as Director of Life Sciences Investment at Temasek International in Singapore, where she led a team to develop new markets across APAC regions. Before that, she served as Director of Temasek’s China Investment Team, devising and implementing the firm’s China healthcare strategy and building an extensive network of leading scientists and innovators across Asia.

Wu Jie received a M.S. degree in biotechnology from Johns Hopkins University, as well as both a M.S. and B.S. degree in engineering from Princeton University. In her free time, she enjoys badminton and multi-day hikes.

Dr. Binsen Li is a Senior Associate at MPM BioImpact and is responsible for investment identification, due diligence and company creation opportunities in the APAC region.

Prior to joining MPM BioImpact, Binsen spent five years at Hillhouse Capital in New York, where he covered global healthcare investments across both the private and public markets. He was responsible for evaluating opportunities through diligence, building financial models, and crafting investment theses grounded in scientific and commercial insight.

Binsen earned his Ph.D. in Biochemistry, Molecular and Structural Biology from the University of California, Los Angeles. His doctoral research focused on amyloid fibrils in Parkinson’s disease using cryo-electron microscopy to inform structure-based therapeutic development. Earlier in his career, Binsen conducted neurobiology research at Harvard Medical School and received his B.A. in Biochemistry, Cellular and Molecular Biology from Connecticut College.

Outside of work, Binsen enjoys running and spending time outdoors with his wife and their tricolor Australian Shepherd, Mocha.

Dr. Hao Xing is an Associate at MPM BioImpact and is responsible for investment identification, due diligence, business development, and company creation activities.

Prior to joining MPM BioImpact, Hao was a management consultant in the New York Office at Bain & Company, advising clients at Fortune 500 companies and Private Equity firms on growth strategies, transformation, and M&A due diligence.

Hao completed his Ph.D. in Biomedical Engineering at Yale University, focusing on understanding and treating diabetic wounds through the lens of biomechanics. During his graduate study, Hao was a venture fellow with Canaan Partners and was elected the President of the Yale Graduate and Professional Student Senate. Hao received his B.S. in Biological Engineering with a minor in Mechanical Engineering from MIT. He was the Co-founding Undergraduate President of the MIT Biotech Group. Hao is an avid ceramicist and home chef outside of the office.